Baxter International (NYSE:BAX – Get Free Report) was upgraded by equities research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research report issued to clients and investors on Monday,Zacks.com reports. Zacks Research also issued estimates for Baxter International’s Q2 2026 earnings at $0.37 EPS, Q3 2026 earnings at $0.52 EPS, Q4 2026 earnings at $0.62 EPS, FY2026 earnings at $1.87 EPS, Q1 2027 earnings at $0.38 EPS, Q2 2027 earnings at $0.40 EPS, Q3 2027 earnings at $0.55 EPS, FY2027 earnings at $1.91 EPS, Q1 2028 earnings at $0.40 EPS and FY2028 earnings at $2.14 EPS.
Several other research analysts also recently commented on BAX. TD Cowen reduced their price objective on Baxter International from $22.00 to $20.00 in a report on Friday, May 1st. Weiss Ratings reissued a “sell (e+)” rating on shares of Baxter International in a research report on Friday, May 15th. Citigroup cut their price target on Baxter International from $21.00 to $19.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 11th. Stifel Nicolaus lowered their price objective on shares of Baxter International from $20.00 to $19.00 in a research note on Friday, May 1st. Finally, Wall Street Zen cut shares of Baxter International from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. Two investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $19.91.
View Our Latest Stock Analysis on BAX
Baxter International Trading Up 1.3%
Baxter International (NYSE:BAX – Get Free Report) last issued its earnings results on Thursday, April 30th. The medical instruments supplier reported $0.36 EPS for the quarter, topping analysts’ consensus estimates of $0.31 by $0.05. The business had revenue of $2.70 billion for the quarter, compared to the consensus estimate of $2.62 billion. Baxter International had a negative net margin of 9.70% and a positive return on equity of 16.15%. The company’s revenue for the quarter was up 2.9% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.62 EPS. On average, research analysts anticipate that Baxter International will post 1.92 EPS for the current year.
Institutional Trading of Baxter International
A number of institutional investors have recently modified their holdings of the company. EverSource Wealth Advisors LLC raised its stake in shares of Baxter International by 35.6% during the 1st quarter. EverSource Wealth Advisors LLC now owns 6,720 shares of the medical instruments supplier’s stock worth $113,000 after acquiring an additional 1,763 shares in the last quarter. Gabelli Funds LLC grew its holdings in Baxter International by 0.6% in the first quarter. Gabelli Funds LLC now owns 498,000 shares of the medical instruments supplier’s stock worth $8,366,000 after purchasing an additional 3,000 shares during the last quarter. Gamco Investors INC. ET AL grew its holdings in Baxter International by 9.2% in the first quarter. Gamco Investors INC. ET AL now owns 427,368 shares of the medical instruments supplier’s stock worth $7,180,000 after purchasing an additional 36,118 shares during the last quarter. Alpha Family Trust acquired a new position in shares of Baxter International during the first quarter worth $182,000. Finally, Bessemer Group Inc. increased its position in shares of Baxter International by 118.6% during the first quarter. Bessemer Group Inc. now owns 9,850 shares of the medical instruments supplier’s stock worth $165,000 after purchasing an additional 5,344 shares in the last quarter. 90.19% of the stock is currently owned by institutional investors.
Baxter International Company Profile
Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company’s primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter’s offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.
In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.
Further Reading
- Five stocks we like better than Baxter International
- Banks Are Buying Back Stock Hand Over Fist, Including These 3 Names
- 2 Aluminum Stocks Poised for Big Tariff-Related Gains
- AutoZone’s Pullback Sets Up a Long-Term Buying Opportunity
- AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.
